For this purpose, a multicenter, open-label, single-arm, phase II study was designed to assess the efficacy and safety of PLD plus trastuzumab and docetaxel for the neoadjuvant treatment of patients with stage II or III HER2-positive BC for the first time. The gene discussed is ERBB2; the disease is breast cancer.